Addex Therapeutics vs Kazia Therapeutics
ADXN and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADXN and KZIA compare
Addex Therapeutics grew revenue faster over the last twelve months (−92.6% versus −98.2% for Kazia Therapeutics).
Kazia Therapeutics scores higher on the StockData Score (1 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADXN | KZIA |
|---|---|---|
| Size and price | ||
| Share price | $3.50 | $5.31 |
| Change, 1 year | −58.7% | −15.3% |
| Change, 5 years | −97.5% | −98.9% |
| Beta (5Y) | 1.95 | 4.08 |
| Employees | 3 | 14 |
| StockData Score | ||
| Total score | 0 | 1 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −92.6% (better) | −98.2% |
| Revenue growth, 5Y average | −61.6% | – |
| EPS growth (TTM) | −186% | – |
| Profitability | ||
| Operating margin | −9391% | – |
| Net margin | – | −49291% |
| FCF margin | −7244% | – |
| Financial health | ||
| Interest coverage | −181.0× | – |
| Current ratio | 0.76 | 2.87 (better) |
| Piotroski F-score | – | 2 |
| Ownership | ||
| Held by institutions | 0.00% | 0.45% |
| Held by insiders | 15.5% | 0.29% |
| Superinvestors holding | – | 1 |
Go deeper
- ADXN stock overview
- ADXN income statement
- ADXN valuation and score
- KZIA stock overview
- KZIA income statement
- KZIA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.